Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.
Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.
Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.